Companies · Biotechnology

Spinal Restoration Inc

AUSTIN · Biotechnology

Diligence memoA one-page analyst read on Spinal Restoration Inc — recommendation, valuation, rhythm, risks.
$23.0M
Total raised · real
2
Rounds
0.1×
Latest step-up
Top 31%
Sector rank · raised
Series B
Latest stage · inferred · Fri Dec 14 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

Spinal Restoration Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.18× the median modeled value of Series B Biotechnology companies in 2010–2012 (48 peers) — value vs value, same stage and era.
Dormant
  • Last raise 13.5 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Spinal Restoration Inc is one of 4291 Biotechnology companies tracked from AUSTIN. By capital raised it ranks in the upper tier (ahead of 70% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries B · 2007-10-03 Raised $20M (real) Modeled valuation $794M (est)$20M$794MSeries B2007Series B · 2012-12-14 Raised $3.0M (real) Modeled valuation $119M (est)$3.0M$119MSeries B2012+$3.0MCumulative $23M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$20.0M · 2007
Series B extension$3.0M · 2012

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$119.1M
Base estimate est.
$6.0M
Conservative case
$458.2M
Upside case
$16.7M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $793.8M · 2007-10-032007Series B · modeled $119.1M · 2012-12-142012
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
54%
Survival probability
36% low · 66% high
1.54×/yr
Annual markup
1.86×/yr upside case
6.0 yr
Elapsed time used
13.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
62 mo
Avg between rounds
$4.4M/yr
Capital velocity
18.7 yr
On record since
2007
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.2× above median
This company$23.0M
Sector median$7.2M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.2× of median
This company$3.0M
Sector median$17.5M
Modeled value — vs sector median (estimate, all stages) 1.9× above median
This company$119.1M
Sector median$64.2M

Raised more than 70% of sector peers (real $). Modeled value above 62% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #41 of 48.

This companyCohort peer
$10.0M$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)Redpoint Bio CORP · Series B Raised $40.0M · modeled $1.6B (est)Cardiaq Valve Technologies Inc · Series B Raised $77.2M · modeled $1.5B (est)Visterra, Inc. · Series B Raised $82.4M · modeled $1.4B (est)Celltex Therapeutics Corp · Series B Raised $34.1M · modeled $1.4B (est)Crown Bioscience, Inc · Series B Raised $87.1M · modeled $1.2B (est)Trius Therapeutics Inc · Series B Raised $49.3M · modeled $1.2B (est)Intercept Pharmaceuticals Inc · Series B Raised $45.0M · modeled $1.2B (est)Crescendo Bioscience, Inc. · Series B Raised $169.8M · modeled $1.1B (est)Allocure Inc · Series B Raised $50.5M · modeled $1.1B (est)Pathwork Diagnostics Inc · Series B Raised $52.5M · modeled $1.0B (est)MethylGene Inc. · Series B Raised $97.2M · modeled $1.0B (est)Predictive Biosciences, Inc · Series B Raised $26.8M · modeled $1.0B (est)Spinal Restoration Inc (this company) Raised $23.0M · modeled $119.1M (est)Spinal Restoration Inc
CompanyStageRaised · realValue · estvs peer med.
Redpoint Bio CORPSeries B$40.0M$1.6B2.44×
Cardiaq Valve Technologies IncSeries B$77.2M$1.5B2.27×
Visterra, Inc.Series B$82.4M$1.4B2.08×
Celltex Therapeutics CorpSeries B$34.1M$1.4B2.07×
Crown Bioscience, IncSeries B$87.1M$1.2B1.86×
Trius Therapeutics IncSeries B$49.3M$1.2B1.84×
Intercept Pharmaceuticals IncSeries B$45.0M$1.2B1.83×
Crescendo Bioscience, Inc.Series B$169.8M$1.1B1.73×
Allocure IncSeries B$50.5M$1.1B1.61×
Pathwork Diagnostics IncSeries B$52.5M$1.0B1.60×
MethylGene Inc.Series B$97.2M$1.0B1.59×
Predictive Biosciences, IncSeries B$26.8M$1.0B1.55×
Spinal Restoration Inc this companySeries B$23.0M$119.1M0.18×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$20.0M2007-10-03$111.1M$793.8M90%
Series B$3.0M2012-12-14$16.7M$119.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$20.0M2007-10-03
    • First recorded raise — entered as Series B.
  2. Series B$3.0M2012-12-14
    • Raised again after 62 mo — slower than the ~14 mo sector norm.
    • Round 6.7× smaller than the prior — bridge or down round.
Intelligence
2018 ~Q1
Modeled next raise · ~62mo cadence
$3.0M
Modeled next size est.range $3.0M$4.8M
0.1×
Last step-up
$4.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Gary Stevenson6 other2012-12
Jerry DeVries3 other2012-12
Joseph C. Aragona2 other2007-10
Gary E. Sabins1 other2007-10
Steve Whitlock1 other2012-12
Gary D. Stevenson2007-10
Gary Sabins2012-12
Gerald L. DeVries2007-10
Jeff Frizell2007-10
Joe Aragona2012-12
Kevin Laland2012-12
Kevin L. Lalande2007-10
Steven I. Whitlock2007-10
Registry & provenance

Spinal Restoration Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1306724
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Mach5 Therapeutics, Inc.BiotechnologySeries B$23.4M$119.4Msame sector · same stage
March Biosciences, Inc.BiotechnologySeries B$22.1M$140.6Msame sector · same stage
EnPlusOne Biosciences Inc.BiotechnologySeries B$21.8M$128.7Msame sector · same stage
Faeth Therapeutics, Inc.BiotechnologySeries B$24.4M$109.3Msame sector · same stage
Insite Vision IncBiotechnologySeries B$24.6M$94.5Msame sector · same stage
Xylocor Therapeutics, Inc.BiotechnologySeries B$21.4M$125.9Msame sector · same stage
Angiex, Inc.BiotechnologySeries B$24.9M$98.5Msame sector · same stage
Lonestar Medicines, Inc.BiotechnologySeries B$25.0M$92.3Msame sector · same stage
Frequently asked
How much funding has Spinal Restoration Inc raised?
Spinal Restoration Inc has raised approximately $23.0M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Spinal Restoration Inc's estimated valuation?
Provath's modeled valuation for Spinal Restoration Inc is approximately $119.1M (modeled range $6.0M–$458.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Spinal Restoration Inc at?
Spinal Restoration Inc's latest modeled financing stage is Series B. Its most recent recorded round closed around Fri Dec 14.
What does Spinal Restoration Inc do and where is it based?
Spinal Restoration Inc operates in the Biotechnology sector, based in AUSTIN.
Explore related

See where Spinal Restoration Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Spinal Restoration Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.